{"id":"NCT01603628","sponsor":"Allergan","briefTitle":"BOTOX® Treatment in Pediatric Lower Limb Spasticity","officialTitle":"BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-09-11","primaryCompletion":"2017-06-28","completion":"2017-06-28","firstPosted":"2012-05-22","resultsPosted":"2018-08-14","lastUpdate":"2018-08-14"},"enrollment":384,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Pediatrics","Muscle Spasticity","Cerebral Palsy"],"interventions":[{"type":"BIOLOGICAL","name":"botulinum toxin Type A","otherNames":["BOTOX®"]},{"type":"DRUG","name":"Normal Saline (Placebo)","otherNames":[]}],"arms":[{"label":"BOTOX® 4 U/kg","type":"EXPERIMENTAL"},{"label":"BOTOX® 8 U/kg","type":"EXPERIMENTAL"},{"label":"Normal Saline (Placebo)","type":"PLACEBO_COMPARATOR"}],"summary":"This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with lower limb spasticity.","primaryOutcome":{"measure":"Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6","timeFrame":"Baseline (Day 1) to Weeks 4 and 6","effectByArm":[{"arm":"BOTOX® 8 U/kg","deltaMin":-1.06,"sd":0.071},{"arm":"BOTOX® 4 U/kg","deltaMin":-1.01,"sd":0.072},{"arm":"Placebo","deltaMin":-0.8,"sd":0.071}],"pValues":[{"comp":"OG000 vs OG002","p":"0.010"},{"comp":"OG001 vs OG002","p":"0.033"}]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":53,"countries":["United States","Hungary","Italy","Philippines","Poland","Russia","South Korea","Thailand","Turkey (Türkiye)"]},"refs":{"pmids":[],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":128},"commonTop":["Viral upper respiratory tract infection","Upper respiratory tract infection","Pyrexia"]}}